Tamara P Miller

List of Publications by Year
in descending order

39 papers	366 citations	840776 11 h-index	839539 18 g-index
40 all docs	40 docs citations	40 times ranked	561 citing authors

#	Article	IF	Citations
1	Challenges and Barriers to Adverse Event Reporting in Clinical Trials: A Childrenâ€™s Oncology Group Report. Journal of Patient Safety, 2022, 18, e672-e679.	1.7	7
2	A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica, 2022, 107, 1185-1188.	3.5	6
3	Pediatric EBV-negative monomorphic postâ€“solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers.. Journal of Clinical Oncology, 2022, 40, 10012-10012.	1.6	1
4	Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatric Blood and Cancer, 2021, 68, e28315.	1.5	1
5	Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia. Leukemia and Lymphoma, 2021, 62, 899-908.	1.3	6
6	Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery. Current Hematologic Malignancy Reports, 2021, 16, 126-131.	2.3	3
7	Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. Pediatric Blood and Cancer, 2021, 68, e28940.	1.5	1
8	Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1970-1970.	1.4	0
9	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. Blood, 2021, 138, 3398-3398.	1.4	3
10	Outcome of Post Solid Organ Transplant Burkitt Lymphoma (PSOT-BL): A Report from the Pediatric PTLD Collaborative (PPC). Blood, 2021, 138, 2498-2498.	1.4	0
11	Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropenia. Pediatric Blood and Cancer, 2020, 67, e28570.	1.5	8
12	Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies. Hematology American Society of Hematology Education Program, 2020, 2020, 280-286.	2.5	4
13	Feasibility and acceptability of an animatronic duck intervention for promoting adaptation to the inâ€patient setting among pediatric patients receiving treatment for cancer. Pediatric Blood and Cancer, 2019, 66, e27984.	1.5	4
14	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. Pediatric Blood and Cancer, 2019, 66, e27747.	1.5	40
15	Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN). Blood, 2019, 134, 333-333.	1.4	3
16	Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium. Blood, 2019, 134, 1304-1304.	1.4	2
17	Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL). Blood, 2019, 134, 5809-5809.	1.4	1
18	Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium. Blood, 2019, 134, 3814-3814.	1.4	0

#	Article	IF	Citations
19	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. Pediatric Critical Care Medicine, 2018, 19, e312-e320.	0.5	10
20	Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. PLoS ONE, 2018, 13, e0192529.	2.5	16
21	Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 369-369.	1.4	3
22	Reply to H.S.L. Jim et al. Journal of Clinical Oncology, 2017, 35, 1135-1135.	1.6	0
23	Using electronic medical record data to report laboratory adverse events. British Journal of Haematology, 2017, 177, 283-286.	2.5	31
24	Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer, 2017, 123, 3781-3790.	4.1	18
25	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. American Journal of Hematology, 2017, 92, 141-148.	4.1	29
26	Complications preceding early deaths in Black and White children with acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26712.	1.5	4
27	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group. Haematologica, 2017, 102, e340-e343.	3.5	4
28	Early discharge as a mediator of greater <scp>ICU</scp>â€level care requirements in patients not enrolled on the <scp>AAML</scp>0531 clinical trial: a Children's Oncology Group report. Cancer Medicine, 2016, 5, 2412-2416.	2.8	4
29	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. Cancer, 2016, 122, 3394-3400.	4.1	8
30	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2016, 34, 1537-1543.	1.6	47
31	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group. Leukemia and Lymphoma, 2016, 57, 1567-1574.	1.3	13
32	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. Cancer Medicine, 2015, 4, 1356-1364.	2.8	17
33	Comparison of administrative/billing data to expected protocolâ€mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1184-1189.	1.5	12
34	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1775-1781.	1.5	21
35	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. Blood, 2015, 126, 530-530.	1.4	0
36	Comparison of Resource Utilization in Children Discharged Versus Children That Remain Hospitalized Following Chemotherapy for Acute Myeloid Leukemia. Blood, 2014, 124, 3697-3697.	1.4	0

#	Article	IF	Citations
37	Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 2286-2286.	1.4	0
38	Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 931-931.	1.4	1
39	Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are ageâ€dependent: Report from Danaâ€Farber Cancer Institute ALL Consortium Protocol 00â€01. Pediatric Blood and Cancer, 2011, 57, 492-498.	1.5	38